Table 2. Risk of developing an SMN and selected sites in 3-year survivors of nonretinoblastoma childhood cancer.

	Nonretinoblastoma cohort (n=15 452)
SMN sites and ICD9 codes	O	SIR	95% CI for SIR
All (exc skin) 1400–2089 (exc 1730–1739)	201	5.8	5.0, 6.7
Digestive 1400–1599	27	8.8	5.8, 12.9
Respiratory 1600–1659	6	4.8	1.7, 10.3
Bone 1700–1709	33	25.2	17.3, 35.4
Soft tissue 1710–1719	15	15.9	8.9, 26.2
Breast (female) 1740–1749	11	2.8	1.4, 5.0
Brain/CNS 1910–1929	42	13.4	9.6, 18.1
Endocrine 1930–1949	13	13.9	7.4, 23.8
Leukaemia 2040–2089	23	6.5	4.2, 9.8

SMN=second malignant neoplasm; O=observed; SIR=standardised incidence ratio; CI=confidence intervals; CNS=central nervous system.